THE US Food and Drug
Administration has issued a
warning over GlaxoSmithKline’s
seizure and bipolar drug Lamictal
(lamotrigine), which its says can
cause aseptic meningitis.
At present the FDA is working
with GSK to update the prescribing
and labelling information.
The agency said that patients on
Lamictal who present with
meningitis with no clear cause should
discontinue the drug immediately.
“Aseptic meningitis is a rare but
serious side effect of Lamictal use,”
said Russell Katz, director of the
Division of Neurology Products in
the FDA’s Center for Drug
Evaluation and Research.
“Patients that experience
symptoms should consult their
health care professional
immediately,” he added.The above article was sent to subscribers in Pharmacy Daily's issue from 13 Aug 10 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 13 Aug 10
PEAK pharmacy bodies are calling on the Australian Government to extend the new Commonwealth Prac Payment to pharmacy students, citing the challenges of “placement poverty” in unpaid practical placements.
AFT Pharmaceuticals is set to develop a topical treatment for keloid and hypertrophic scarring in partnership with NZ’s Massey Ventures, the commercialisation arm of Massey University, and the Gillies McIndoe Research Institute.
THE Pharmaceutical Society of Australia (PSA) awarded Brooke Shelly the prestigious 2024 PSA MIMS Credentialed Pharmacist of the Year award last Fri at the Credentialed Pharmacist Conference (CPC24) (PD breaking news).
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.